ÐÂÎÅ×ÊѶ
Z6ÈËÉú¾ÍÊDz©ÖÆÒ©WP203A»ñÃÀ¹úFDAÊÚÓèÖÎÁÆÌìðå´¯µÄ¹Â¶ùÒ©È϶¨
ÈÕÆÚ£º
2026Äê04ÔÂ02ÈÕ 15:03
½üÈÕ £¬Z6ÈËÉú¾ÍÊDz©ÖÆÒ©ÔÚÑÐÐÂÒ©WP203A£¨°¢·¨ÅµëÄ £¬afamelanotide£©»ñµÃÃÀ¹úFDAÊÚÓèµÄÖÎÁÆÌìðå´¯£¨pemphigus£©µÄ¹Â¶ùÒ©×ʸñÈ϶¨¡£¸ºÔðÈËÕԹڼײ©Ê¿±íʾ £¬“Ä¿Ç°ÎÒÃÇÕý»ý¼«ÍƽøWP203AÔÚÈ«Çò·¶Î§µÄÐÂÒ©¿ª·¢ £¬ÆÚ´ý¸ü¶àµÄÌìðå´¯»¼ÕßÄܹ»ÔçÈÕÓÃÉÏÕâһеÄÖÎÁÆÑ¡Ôñ¡£”
¹ØÓÚWP203A£¨°¢·¨ÅµëÄ £¬afamelanotide£©
ºÚËØƤÖÊËØÊÜÌ壨MCR£©ÏµÍ³ÔÚÈËÌåÖз¢»Ó×ŶàÖÖÉúÀí¹¦ÄÜ £¬°üÀ¨µ÷½ÚÑ×Ö¢·´Ó¦¡¢ÃâÒßϵͳÏìÓ¦¡¢´úл¡¢Ê³ÎïÉãÈëÒÔ¼°×éÖ¯ÐÞ¸´µÈ¡£Õâ¸öϵͳ°üº¬ÎåÖÖ²»Í¬µÄÊÜÌå——MC1RÖÁMC5R £¬Í¨¹ý¼¤»îÌض¨µÄºÚËØƤÖÊËØÊÜÌå £¬¿ÉÒÔ·¢»ÓÖî¶à×÷Óà £¬ÀýÈç¼õÉÙϸ°ûÓ¦¼¤¡¢¸ÄÉÆÑ×Ö¢×´¿ö £¬²¢´Ù½ø×éÖ¯ÐÞ¸´¡£WP203AÊÇÒ»ÖֺϳɵĺÚƤÖÊËØÊÜÌ弤¶¯¼Á £¬Ö÷Ҫͨ¹ý¼¤»îMC1R·¢»ÓÖÎÁÆ×÷Óà £¬¾ßÌå×÷ÓûúÖƱíÏÖΪ£º
1.¶Ô¿¹Ñõ»¯Ó¦¼¤£ºÍ¨¹ýÉϵ÷ת¼Òò×ÓNrf2 £¬¾ÀÕý»úÌåµÄ¿¹Ñõ»¯/Ñõ»¯Ê§ºâ £¬´Ó¶ø¼õÇáÑõ»¯Ó¦¼¤¶ÔƤ·ôµÄËðÉË¡£
2.µ÷½ÚÃâÒßÓëÑ×Ö¢£ºÍ¨¹ý×÷ÓÃÓÚºÚËØƤÖÊËØÊÜÌå £¬Ò»·½ÃæÒÖÖƶàÖÖ´ÙÑ×ϸ°ûÒò×Ó £¬ÁíÒ»·½Ãæµ÷½ÚTÁÜ°Íϸ°û¹¦Äܲ¢ÓÕµ¼¾ßÓп¹Ñ××÷Óõĵ÷½ÚÐÔTϸ°û £¬´Ó¶ø»Ö¸´ÃâÒßƽºâ¡£
3.´Ù½øƤ·ôÓúºÏ£ºÀûÓúÚËØƤÖÊËØ»¯ºÏÎï¹ÌÓеÄDZÁ¦ £¬´Ù½øÓɼ¬²ãËɽ⵼ÖµÄƤ·ôÀ£ÑñºÍÉË¿ÚµÄÐÞ¸´¡£
ÔÚÃÀ¹ú £¬°¢·¨ÅµëÄÒѱ»³É¹¦Ó¦ÓÃÓÚÖÎÁƺìϸ°ûÉú³ÉÐÔÔß²ßø²¡£¨EPP£© £¬ÆäÁÙ´²Ó¦Óò»½öÑéÖ¤ÁËMC1R¼¤¶¯¼ÁµÄ°²È«ÐÔ £¬¸üÕ¹ÏÖ³öÏÔÖøµÄ¿¹Ñ×DZÁ¦ £¬ÎªÍØÕ¹ÆäÔÚÆäËûÑ×Ö¢ÐÔºÍ×ÔÉíÃâÒßÐÔƤ·ô²¡ÖеÄÓ¦ÓÃÌṩÁËÓÐÁ¦Ö§³Å¡£´Ë´ÎFDAÊÚÓèµÄ¹Â¶ùÒ©×ʸñÈ϶¨ £¬×÷ΪZ6ÈËÉú¾ÍÊDz©ÖÆÒ©WP203A¿ª·¢ÁìÓòµÄÒ»²¿·Ö £¬½«½øÒ»²½ÎªWP203A¿ª·¢Ð¼ÁÐÍ¡¢ÐÂÊÊÓ¦Ö¢¡¢ÐÂÊг¡µÈ´´ÐÂÐÔ²¼¾ÖÌṩÓÐÁ¦Ö§³ÅÓë±£ÕÏ¡£
¹ØÓÚÌìðå´¯
Ììðå´¯ÊÇÒ»Àັ¼ûµÄÑÏÖØÍþвÈËÀཡ¿µµÄ×ÔÉíÃâÒßÐÔƤ·ôð¤Ä¤´óðåÐÔ¼²²¡ £¬ÃâÒßϵͳ´íÎóµØ¹¥»÷Ƥ·ô±í²ã£¨±íƤ£©ºÍճĤµÄϸ°û £¬µ¼ÖÂƤ·ôË®ÅݵÄÐγɡ£±íÏÖΪð¤Ä¤ºÍƤ·ôÉÏƤµÄË®ÅݺÍÃÓÀà £¬Í¨³£»áÑÏÖØÓ°ÏìÉú»îÖÊÁ¿ £¬ÉõÖÁ¿ÉÄÜÖÂÃü¡£¶àÊýÑ°³£ÐÍÌìðå´¯£¨PV£©»¼Õß×îÏȳöÏÖ¿ÚÇ»Ë𺦠£¬Ëæºó³öÏÖƤ·ô²¡±ä¡£¿ÚÇ»²¡±ä³£¼ûÓÚ¼Õð¤Ä¤ºÍÑʲ¿ £¬±íÏÖΪ³ÖÐøÐÔ¡¢ÌÛÍ´ÐÔÃÓÀûòÀ£Ññ £¬ÑÏÖØÓ°Ïì½øʳ£»ÉúÖ³Æ÷ð¤Ä¤ºÍÑÛ½áĤҲ¿ÉÄÜÊÜÀÛ¡£Æ¤·ô²¡±ä±íÏÖΪËɳÚÐÔË®ðåºÍ´óðå £¬³£¼ûÓÚÕý³£Æ¤·ô±íÃæ £¬Ë®ðåÒ×ÆÆÁÑ £¬ÐγÉÀ©´óÐÔÃÓÀÃÃæ £¬NikolskyÕ÷ÑôÐÔ¡£¶àÊý»¼ÕßÎÞðþÑ÷Ö¢×´¡£Æ¤ËðºÃ·¢ÓÚÐر³²¿¡¢Ã沿¡¢Í·²¿¡¢Ò¸ÎÑ¡¢¸¹¹É¹µ¡¢Íβ¿µÈ¡£ Ä¿Ç°Ììðå´¯µÄÈ·Çв¡ÒòÉÐδÍêÈ«²ûÃ÷ £¬µ«ÒÅ´«¡¢ÃâÒßÓë»·¾³ÒòËØÔÚÌìðå´¯µÄ·¢ÉúÖз¢»ÓÖØÒª×÷Óá£ÒÅ´«ÒòËØÊÇÌìðå´¯µÄÖ÷Òª·çÏÕÒòËØÖ®Ò»£»×ÔÉí¿¹ÌålgG¹¥»÷ÇÅÁ£Ð¾Ìǵ°°×Dsg1ºÍ/»òDsg3µ¼ÖÂÆäʧȥճ¸½¹¦ÄÜ £¬ÊÇÌìðå´¯·¢²¡µÄºËÐÄ»úÖÆ¡£
Ììðå´¯µÄÖÎÁÆÊܵ½¸Ã²¡µÄº±¼ûÐÔ¼°È±·¦Ëæ»ú¶ÔÕÕÊÔÑ飨RCTs£©µÄÏÞÖÆ¡£ÏÖÓеÄÖÎÁÆÊÖ¶ÎÏà¶Ôµ¥Ò» £¬È«ÉíÐÔƤÖÊÀà¹Ì´¼ÈÔÈ»ÊÇÖ÷ÒªÖÎÁÆÊֶΠ£¬Óë¿Ú·þÁòßòàÑßÊ»òù·ÓËáÀ໯ºÏÎÈçù·ÓËáõ¥»òù·ÓËáÄÆ£©ÁªºÏʹÓÃÀ´»º½â¼²²¡½øÕ¹ ¡¢¼õÉÙ²»Á¼·´Ó¦ºÍ¸´·¢Çé¿ö¡£È»¶ø £¬¸ß´ï50%µÄ»¼Õ߻Ḵ·¢ £¬65%µÄ»¼Õß»á¾ÀúÓëÃâÒßÒÖÖƼÁÏà¹ØµÄÑÏÖز»Á¼Ê¼þ £¬Ô¼°ëÊý»¼ÕßÔÚ3ÄêºóÈÔÐè³ÖÐøÀà¹Ì´¼ÖÎÁÆ¡£ÀûÍ×Îôµ¥¿¹Í¨¹ýÕë¶ÔBÁÜ°Íϸ°ûCD20¿¹Ô»º½âÔçÆÚ¼²²¡½ø³Ì£»¶ÈÆÕÀûÓȵ¥¿¹×÷ΪȫÇòÊ׸öÖÎÁƳÉÈË´óðåÐÔÀàÌìðå´¯£¨BP£©µÄ°ÐÏòÒ©Îï £¬Í¨¹ýÒÖÖÆ°×ϸ°û½éËØ-4ºÍ°×ϸ°û½éËØ-13ÐźÅͨ·»º½â¼²²¡½ø³Ì¡£×ÛÉÏ £¬ÏÖÓÐÒ©ÎïÆÕ±é´æÔÚ»úÖƵ¥Ò»¡¢Ò׸´·¢¡¢²»Á¼·´Ó¦¶àÇÒ·¢ÉúÂʸ߻òÖÎÁÆ·ÑÓø߰ºµÄ¾ÖÏÞ[9,10] £¬¶àÊý»¼ÕßµÄÁÙ´²ÖÎÁÆÐèÇóÈÔÑÏÖØδÂú×ã¡£
¹ØÓÚFDA¹Â¶ùÒ©È϶¨
¹Â¶ùÒ©£¨orphan drug£©ÊÇFDAΪ¹ÄÀøº±¼û²¡ÖÎÁÆÒ©ÎïµÄ¿ª·¢¶øÉèÁ¢µÄÒ»ÖÖ×ʸñÈ϶¨ £¬ÎªÐÂÒ©¿ª·¢ÌṩһϵÁеļ¤Àø £¬°üÀ¨´ÓÒ©Æ·ÉÏÊлñÅúºó¿ªÊ¼µÄ7ÄêµÄÊг¡×¨ÓªÈ¨£¨market exclusivity£©¡¢ÐÂÒ©ÉêÇ루NDA£©µÄÓÅÏÈÉóÆÀÉóÅú£¨Óлú»á¼ÓËÙÒ©Æ·ÁÙ´²Ñо¿¡¢ÉÏÊеĽø³Ì£©¡¢ÁÙ´²¿ª·¢¹ý³ÌÖÐÃÜÇÐÖ¸µ¼ÓëÖ§³Ö £¬ÒÔ¼°ÐÂÒ©×¢²á·ÑÓõÄÃâ³ý£¨2025ÄêÃÀ¹úFDAÐÂÒ©×¢²áÉêÇë·ÑԼΪ3100ÍòÈËÃñ±Ò£©¡£
²Î¿¼ÆäËû»ñµÃFDA¹Â¶ùÒ©È϶¨µÄ¡¢Õë¶Ô´æÔÚÑÏÖØδÂú×ãÁÙ´²ÐèÇóµÄ¼²²¡µÄÒ©Æ·Çé¿ö £¬ÒÔ¼°WiseGuy Report¡¢±´ÕÜ˹×ÉѯµÈ»ú¹¹µÄ¹«¿ªµ÷ÑÐÊý¾Ý £¬¹«Ë¾Ô¤ÆÚδÀ´Ò©Æ·ÉÏÊÐºó £¬ÓÐÍûÔÚÖйúºÍÃÀ¹úÊг¡ÊµÏÖ°ÙÒÚÈËÃñ±Ò¼¶±ðµÄÄêÏúÊÛ¡£
ÎÄÕÂתÔØ×Ô²ÆÁªÉç
²Î¿¼ÎÄÏ×
[1] Haycock J W, Rowe S J, Cartledge S, et al. Alpha-melanocyte-stimulating hormone reduces impact of proinflammatory cytokine and peroxide-generated oxidative stress on keratinocyte and melanoma cell lines[J]. J Biol Chem, 2000, 275(21):15629-36.
[2] Mehta P, Kaye W, Raymond J, et al. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(46):1285-1289.
[3] Wang W, Guo D Y, Lin Y J, et al. Melanocortin Regulation of Inflammation[J]. Front Endocrinol (Lausanne), 2019, 10:683.
[4] Auriemma M, Brzoska T, Klenner L, et al. alpha-MSH-stimulated tolerogenic dendritic cells induce functional regulatory T cells and ameliorate ongoing skin inflammation[J]. J Invest Dermatol, 2012, 132(7):1814-24.
[5] Bystryn J C, Rudolph J L. Pemphigus[J]. Lancet, 2005, 366(9479):61-73.
[6] Murrell D F, Dick S, Ahmed A R, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus[J]. J Am Acad Dermatol, 2008, 58(6):1043-6.
[7] Herbst A, Bystryn J C. Patterns of remission in pemphigus vulgaris[J]. J Am Acad Dermatol, 2000, 42(3):422-7.
[8] Bohm M, Luger T. Are melanocortin peptides future therapeutics for cutaneous wound healing?[J]. Exp Dermatol, 2019, 28(3):219-224.
[9] Minder E I, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders[J]. Clin Pharmacokinet, 2017, 56(8):815-823.
[10] Understanding the Unmet Needs of the Pemphigus & Pemphigoid Community. IPPF Externally-Led Patient-Focused Drug Development Meeting, January 25, 2023
[11] https://www.gelonghui.com/p/2071680
[12] https://pre.gelonghui.com/p/2502356
[13] https://www.wiseguyreports.com/cn/reports/mucous-membrane-pemphigoid-treatments-market
Ïà¹ØÍƼö
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ̨ÖÝ